The cost-effectiveness of implementing HPV testing for cervical cancer screening in El Salvador

Nicole G. Campos, Mauricio Maza, Karla Alfaro, Julia C. Gage, Philip E. Castle, Juan C. Felix, Rachel Masch, Miriam Cremer, Jane J. Kim

Research output: Contribution to journalArticle

Abstract

Objective: To assess the cost-effectiveness of HPV-based screening and management algorithms for HPV-positive women in phase 2 of the Cervical Cancer Prevention in El Salvador (CAPE) demonstration, relative to the status quo of Pap-based screening. Methods: Data from phase 2 of the CAPE demonstration (n=8000 women) were used to inform a mathematical model of HPV infection and cervical cancer. The model was used to project the lifetime health and economic outcomes of HPV testing every 5 years (age 30–65 years), with referral to colposcopy for HPV-positive women; HPV testing every 5 years (age 30–65 years), with immediate cryotherapy for eligible HPV-positive women; and Pap testing every 2 years (age 20–65 years), with referral to colposcopy for Pap-positive women. Results: Despite slight decreases in the proportion of HPV-positive women who received treatment relative to phase 1, the health impact of screening in phase 2 remained stable, reducing cancer risk by 58.5%. As in phase 1, HPV testing followed by cryotherapy for eligible HPV-positive women remained the least costly and most effective strategy (US$490 per year of life saved). Conclusion: HPV-based screening followed by immediate cryotherapy in all eligible women would be very cost-effective in El Salvador.

Original languageEnglish (US)
Pages (from-to)40-46
Number of pages7
JournalInternational Journal of Gynecology and Obstetrics
Volume145
Issue number1
DOIs
StatePublished - Apr 1 2019

Fingerprint

El Salvador
Early Detection of Cancer
Uterine Cervical Neoplasms
Cost-Benefit Analysis
Cryotherapy
Colposcopy
Referral and Consultation
Health
Neoplasms
Theoretical Models
Economics
Costs and Cost Analysis

Keywords

  • Cancer screening
  • Cost-effectiveness analysis
  • Decision analysis
  • El Salvador
  • HPV DNA tests
  • Human papillomavirus (HPV)
  • Mathematical model
  • Uterine cervical neoplasms

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

The cost-effectiveness of implementing HPV testing for cervical cancer screening in El Salvador. / Campos, Nicole G.; Maza, Mauricio; Alfaro, Karla; Gage, Julia C.; Castle, Philip E.; Felix, Juan C.; Masch, Rachel; Cremer, Miriam; Kim, Jane J.

In: International Journal of Gynecology and Obstetrics, Vol. 145, No. 1, 01.04.2019, p. 40-46.

Research output: Contribution to journalArticle

Campos, Nicole G. ; Maza, Mauricio ; Alfaro, Karla ; Gage, Julia C. ; Castle, Philip E. ; Felix, Juan C. ; Masch, Rachel ; Cremer, Miriam ; Kim, Jane J. / The cost-effectiveness of implementing HPV testing for cervical cancer screening in El Salvador. In: International Journal of Gynecology and Obstetrics. 2019 ; Vol. 145, No. 1. pp. 40-46.
@article{62d27f1f4a0742bc810d40b56bc6b784,
title = "The cost-effectiveness of implementing HPV testing for cervical cancer screening in El Salvador",
abstract = "Objective: To assess the cost-effectiveness of HPV-based screening and management algorithms for HPV-positive women in phase 2 of the Cervical Cancer Prevention in El Salvador (CAPE) demonstration, relative to the status quo of Pap-based screening. Methods: Data from phase 2 of the CAPE demonstration (n=8000 women) were used to inform a mathematical model of HPV infection and cervical cancer. The model was used to project the lifetime health and economic outcomes of HPV testing every 5 years (age 30–65 years), with referral to colposcopy for HPV-positive women; HPV testing every 5 years (age 30–65 years), with immediate cryotherapy for eligible HPV-positive women; and Pap testing every 2 years (age 20–65 years), with referral to colposcopy for Pap-positive women. Results: Despite slight decreases in the proportion of HPV-positive women who received treatment relative to phase 1, the health impact of screening in phase 2 remained stable, reducing cancer risk by 58.5{\%}. As in phase 1, HPV testing followed by cryotherapy for eligible HPV-positive women remained the least costly and most effective strategy (US$490 per year of life saved). Conclusion: HPV-based screening followed by immediate cryotherapy in all eligible women would be very cost-effective in El Salvador.",
keywords = "Cancer screening, Cost-effectiveness analysis, Decision analysis, El Salvador, HPV DNA tests, Human papillomavirus (HPV), Mathematical model, Uterine cervical neoplasms",
author = "Campos, {Nicole G.} and Mauricio Maza and Karla Alfaro and Gage, {Julia C.} and Castle, {Philip E.} and Felix, {Juan C.} and Rachel Masch and Miriam Cremer and Kim, {Jane J.}",
year = "2019",
month = "4",
day = "1",
doi = "10.1002/ijgo.12773",
language = "English (US)",
volume = "145",
pages = "40--46",
journal = "International Journal of Gynecology and Obstetrics",
issn = "0020-7292",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - The cost-effectiveness of implementing HPV testing for cervical cancer screening in El Salvador

AU - Campos, Nicole G.

AU - Maza, Mauricio

AU - Alfaro, Karla

AU - Gage, Julia C.

AU - Castle, Philip E.

AU - Felix, Juan C.

AU - Masch, Rachel

AU - Cremer, Miriam

AU - Kim, Jane J.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Objective: To assess the cost-effectiveness of HPV-based screening and management algorithms for HPV-positive women in phase 2 of the Cervical Cancer Prevention in El Salvador (CAPE) demonstration, relative to the status quo of Pap-based screening. Methods: Data from phase 2 of the CAPE demonstration (n=8000 women) were used to inform a mathematical model of HPV infection and cervical cancer. The model was used to project the lifetime health and economic outcomes of HPV testing every 5 years (age 30–65 years), with referral to colposcopy for HPV-positive women; HPV testing every 5 years (age 30–65 years), with immediate cryotherapy for eligible HPV-positive women; and Pap testing every 2 years (age 20–65 years), with referral to colposcopy for Pap-positive women. Results: Despite slight decreases in the proportion of HPV-positive women who received treatment relative to phase 1, the health impact of screening in phase 2 remained stable, reducing cancer risk by 58.5%. As in phase 1, HPV testing followed by cryotherapy for eligible HPV-positive women remained the least costly and most effective strategy (US$490 per year of life saved). Conclusion: HPV-based screening followed by immediate cryotherapy in all eligible women would be very cost-effective in El Salvador.

AB - Objective: To assess the cost-effectiveness of HPV-based screening and management algorithms for HPV-positive women in phase 2 of the Cervical Cancer Prevention in El Salvador (CAPE) demonstration, relative to the status quo of Pap-based screening. Methods: Data from phase 2 of the CAPE demonstration (n=8000 women) were used to inform a mathematical model of HPV infection and cervical cancer. The model was used to project the lifetime health and economic outcomes of HPV testing every 5 years (age 30–65 years), with referral to colposcopy for HPV-positive women; HPV testing every 5 years (age 30–65 years), with immediate cryotherapy for eligible HPV-positive women; and Pap testing every 2 years (age 20–65 years), with referral to colposcopy for Pap-positive women. Results: Despite slight decreases in the proportion of HPV-positive women who received treatment relative to phase 1, the health impact of screening in phase 2 remained stable, reducing cancer risk by 58.5%. As in phase 1, HPV testing followed by cryotherapy for eligible HPV-positive women remained the least costly and most effective strategy (US$490 per year of life saved). Conclusion: HPV-based screening followed by immediate cryotherapy in all eligible women would be very cost-effective in El Salvador.

KW - Cancer screening

KW - Cost-effectiveness analysis

KW - Decision analysis

KW - El Salvador

KW - HPV DNA tests

KW - Human papillomavirus (HPV)

KW - Mathematical model

KW - Uterine cervical neoplasms

UR - http://www.scopus.com/inward/record.url?scp=85062764789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062764789&partnerID=8YFLogxK

U2 - 10.1002/ijgo.12773

DO - 10.1002/ijgo.12773

M3 - Article

C2 - 30702142

AN - SCOPUS:85062764789

VL - 145

SP - 40

EP - 46

JO - International Journal of Gynecology and Obstetrics

JF - International Journal of Gynecology and Obstetrics

SN - 0020-7292

IS - 1

ER -